Patient series
| . | Wet laboratory . | In silico . | |
|---|---|---|---|
| SAL . | Bologna . | TCGA* . | |
| No. of patients | 40 | 24 | 147 |
| Males/females, n | 26/14 | 17/7 | 81/66 |
| Age, n | |||
| 0-14 y | 0 | 0 | 0 |
| 15-39 y | 2 | 3 | 27 |
| 40-59 y | 13 | 12 | 45 |
| >60 y | 25 | 9 | 75 |
| WBC count at presentation, median (range), ×103/μL | 10.55 (0.8-218.5) | 45 (1.5-153) | 20 (1-297) |
| Percentage of BM blasts, median (range) | 63.7 (30-90) | 16.5 (0.4-57) | 72 (11-99) |
| Cytogenetic risk group, n (%) | |||
| ELN favorable | 0 (0) | 6 (26.1) | 17 (12) |
| ELN intermediate | 0 (0) | 7 (30.4) | 96 (65) |
| ELN adverse | 40 (100) | 5 (21.7) | 32 (22) |
| NA | 0 (0) | 5 (21.7) | 2 (1) |
| TP53 status | |||
| Mutated | 40 | 2 | 14 |
| WT | 0 | 22 | — |
| Not tested/not available | — | — | 133 |
| Induction chemotherapy | |||
| 7 + 3 | 5 | 2 | 113 |
| Fludarabine based | — | 8 | — |
| Daunorubicin + cytarabine | 21 | 0 | — |
| MAV | 12 | 5 | — |
| HMAs | — | 3 | 14 |
| Lenalidomide | 1 | — | 9 |
| Other | 1 | 6 | 11 |
| Cohort-wide OS (mo from diagnosis), median (range) | 5.06 (0.03-158.3) | 16.5 (0.3-57) | 15.5 (0.1-118.1) |
| . | Wet laboratory . | In silico . | |
|---|---|---|---|
| SAL . | Bologna . | TCGA* . | |
| No. of patients | 40 | 24 | 147 |
| Males/females, n | 26/14 | 17/7 | 81/66 |
| Age, n | |||
| 0-14 y | 0 | 0 | 0 |
| 15-39 y | 2 | 3 | 27 |
| 40-59 y | 13 | 12 | 45 |
| >60 y | 25 | 9 | 75 |
| WBC count at presentation, median (range), ×103/μL | 10.55 (0.8-218.5) | 45 (1.5-153) | 20 (1-297) |
| Percentage of BM blasts, median (range) | 63.7 (30-90) | 16.5 (0.4-57) | 72 (11-99) |
| Cytogenetic risk group, n (%) | |||
| ELN favorable | 0 (0) | 6 (26.1) | 17 (12) |
| ELN intermediate | 0 (0) | 7 (30.4) | 96 (65) |
| ELN adverse | 40 (100) | 5 (21.7) | 32 (22) |
| NA | 0 (0) | 5 (21.7) | 2 (1) |
| TP53 status | |||
| Mutated | 40 | 2 | 14 |
| WT | 0 | 22 | — |
| Not tested/not available | — | — | 133 |
| Induction chemotherapy | |||
| 7 + 3 | 5 | 2 | 113 |
| Fludarabine based | — | 8 | — |
| Daunorubicin + cytarabine | 21 | 0 | — |
| MAV | 12 | 5 | — |
| HMAs | — | 3 | 14 |
| Lenalidomide | 1 | — | 9 |
| Other | 1 | 6 | 11 |
| Cohort-wide OS (mo from diagnosis), median (range) | 5.06 (0.03-158.3) | 16.5 (0.3-57) | 15.5 (0.1-118.1) |
SAL, Studien-Allianz Leukämie; ELN, European Leukemia-Net; HMAs, hypomethylating agents; MAV, mitoxantrone, cytarabine, and etoposide; WBC, white blood cell.
Cases of newly diagnosed nonpromyelocytic AML with RNA-sequencing data and clinical annotation.